Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 2/20 | 0.37 |
| ▸ | TNF | P01375 | 1/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 2/20 | 0.33 |
| ▸ | CCR8 | P51685 | 1/20 | 0.33 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.33 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.31 |
| ▸ | BTK | Q06187 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21577708 | 0.79 | KMT2A (0.35) | ERN1TNFRIPK1CCR8TRIM24 | |
| SCHEMBL24340277 | 0.77 | TRIM24 (0.43) | PARP1CCR8TRIM24TRIM33KMT2A | |
| SCHEMBL2542070 | 0.77 | TNF (0.45) | TNFRIPK1PARP1CCR8KMT2A | |
| SCHEMBL19584833 | 0.77 | PIM1 (0.31) | CCR8TRIM24TRIM33CYP2A6IMPDH2 | |
| SCHEMBL15321713 | 0.74 | MCL1 (0.35) | CCR8TRIM24TRIM33KMT2ACYP2A6 | |
| SCHEMBL12033199 | 0.71 | TNF (0.41) | TNFRIPK1PARP1CCR8KMT2A | |
| SCHEMBL12513769 | 0.69 | TNF (0.39) | TNFRIPK1PARP1CCR8KMT2A | |
| SCHEMBL620047 | 0.69 | TNF (0.39) | TNFRIPK1PARP1CCR8KMT2A | |
| SCHEMBL6437291 | 0.69 | TNF (0.48) | TNFRIPK1PARP1CCR8KMT2A | |
| SCHEMBL6870752 | 0.69 | TNF (0.39) | TNFRIPK1PARP1CCR8BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024129896-A1 | INHIBITORS OF PROCASPASE-6 ACTIVATION AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-06-20 | — | — | WO | disclosed |
| CN-112608320-B | Piperidine compound and preparation method and medical application thereof | 中国药科大学 | 2023-03-17 | — | — | CN | disclosed |
| EP-3455212-B1 | INHIBITORS OF PROTEASE-ACTIVATED RECEPTOR-2 | HEPTARES THERAPEUTICS LTD (GB) | 2022-02-09 | — | — | EP | disclosed |
| EP-3455212-B1 | INHIBITORS OF PROTEASE-ACTIVATED RECEPTOR-2 | HEPTARES THERAPEUTICS LTD (GB) | 2022-02-09 | — | — | EP | disclosed |
| WO-2021143792-A1 | PIPERIDINE COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 中国药科大学 | 2021-07-22 | — | — | WO | disclosed |
| US-10995072-B2 | Inhibitors of protease-activated receptor-2 | HEPTARES THERAPEUTICS LIMITED (GB) | 2021-05-04 | — | — | US | disclosed |
| US-10995072-B2 | Inhibitors of protease-activated receptor-2 | HEPTARES THERAPEUTICS LIMITED (GB) | 2021-05-04 | — | — | US | disclosed |
| CN-112608320-A | Piperidine compound and preparation method and medical application thereof | 中国药科大学 | 2021-04-06 | — | — | CN | disclosed |
| US-20200140392-A1 | INHIBITORS OF PROTEASE-ACTIVATED RECEPTOR-2 | NXERA PHARMA UK LIMITED (GB) | 2020-05-07 | — | — | US | disclosed |
| US-20200140392-A1 | INHIBITORS OF PROTEASE-ACTIVATED RECEPTOR-2 | NXERA PHARMA UK LIMITED (GB) | 2020-05-07 | — | — | US | disclosed |
| EP-1299382-A4 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED INDOLEOXOACETIC PIPERAZINE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2004-02-11 | — | — | EP | disclosed |
| US-6573262-B2 | Compounds for treating mammals infected with HIV virus | BRISTOL-MYERS SQIBB COMPANY | 2003-06-03 | — | — | US | disclosed |
| US-20030069245-A1 | Composition and antiviral activity of substituted indoleoxoacetic piperazine derivatives | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2003-04-10 | — | — | US | disclosed |
| EP-1299382-A1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED INDOLEOXOACETIC PIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-04-09 | — | — | EP | disclosed |
| US-6469006-B1 | PARTICULARLY FOR TREATING HIV INFECTIONS | BRISTOL-MYERS SQUIBB COMPANY | 2002-10-22 | — | — | US | disclosed |
| WO-2002004440-A1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED INDOLEOXOACETIC PIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-01-17 | — | — | WO | disclosed |
| EP-1105135-A4 | ANTIVIRAL INDOLEOXOACETYL PIPERAZINE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2001-12-12 | — | — | EP | disclosed |
| CN-1320037-A | Antiviral indoloxoacetylpiperazine derivatives | BRISTOL MYERS SQUIBB CO (US) | 2001-10-31 | — | — | CN | disclosed |
| EP-1105135-A1 | ANTIVIRAL INDOLEOXOACETYL PIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-06-13 | — | — | EP | disclosed |
| WO-2000076521-A1 | ANTIVIRAL INDOLEOXOACETYL PIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069245-A1 | Composition and antiviral activity of substituted indoleoxoacetic piperazine derivatives | IDO1, IDO2, ITPA | ERN1 3563/4885TNF 563/4885RIPK1 803/4885 |
| US-10995072-B2 | Inhibitors of protease-activated receptor-2 | F2RL1, F2R, F2RL3 | ERN1 3050/4885TNF 1054/4885RIPK1 527/4885 |
| US-20200140392-A1 | INHIBITORS OF PROTEASE-ACTIVATED RECEPTOR-2 | F2RL1, F2R, F2RL3 | ERN1 3050/4885TNF 1054/4885RIPK1 527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.